This is a multicenter, open-label, multiple-dose, FIH Phase 1/2a trial. The Phase 1 portion uses Bayesian optimal interval (BOIN) design to escalate and determine the MTD and/or RP2D with potential backfill cohorts. The Phase 2a portion consists of dose optimization followed by cohort expansion to confirm safety and tolerability and to further evaluate the efficacy of the selected RP2D in selected solid tumor malignancies for VBC108.
Eligibility
Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria:
1. The participant or the participant's legally acceptable representative is willing and able to provide a written ICF before initiating any trial procedure.
2. Histologically or cytologically confirmed unresectable advanced/metastatic solid tumor .
3. At least one measurable lesion as assessed by the investigator according to RECIST v1.1 criteria.
4. Male or female adults (defined as ≥ 18 years of age).
5. ECOG performance status 0-1.
6. Life expectancy greater than 12 weeks.
7. Archived tumor tissue sample available or able to undergo a fresh biopsy collection.
8. Adequate organ and bone marrow function.
9. Participants must meet the minimum washout period requirements before the first dose of investigational drug.
Exclusion Criteria:
1. Any unresolved toxicity of Grade ≥2 from previous anti-cancer treatment.
2. Known or suspected brain metastases, or spinal cord compression.
3. Prior treatment with an ADC targeting CLDN18.2x CDH17 bispecific ADC.
4. Prior treatment with any ADC carrying a topoisomerase I inhibitor (TOP1i) payload.
5. Prior treatment with CLDN18.2 targeting CAR-T.
Primary outcome measure(s)
Incidence of dose-limiting toxicities (DLT) as defined in the protocol — From time of first dose of VBC108 to end of DLT period ( 21 days) Number of patients with at least 1 dose-limiting toxicity (DLT), which is any toxicity defined as a DLT in the Clinical Study Protocol
Incidence of Serious Adverse Events — From time of Informed Consent to 30 days post last dose of VBC108 Number of patients with serious adverse events by system organ class and preferred term
Incidence of Adverse Events (AEs) — From time of Informed Consent to 30 days post last dose of VBC108 Number of patients with adverse events by system organ class and preferred term
Objective Response Rate (ORR) — From first dose of VBC108 to disease progression or death, up to approximately 2 years The percentage or number of patients with a confirmed investigator assessed complete or partial response according to response criteria in solid tumours (RECIST v1.1)
Trial sites (12)
Facility
City
Region
Status
City of Hope Medical Center
Duarte
California
Recruiting
START Midwest, LLC
Grand Rapids
Michigan
Recruiting
Laura and Issac Perlmutter Cancer Center
New York
New York
Not Yet Recruiting
Next Oncology - Oncology
San Antonio
Texas
Recruiting
NEXT Oncology Virginia
Fairfax
Virginia
Recruiting
GenesisCare North Shore
St Leonards
New South Wales
Recruiting
One Clinical Research
Perth
Western Australia
Not Yet Recruiting
Beijing Cancer Hospital
Beijing
Beijing Municipality
Not Yet Recruiting
Beijing GoBroad Hospital
Beijing
Beijing Municipality
Not Yet Recruiting
Zhongshan Hospital
Shanghai
Shanghai Municipality
Not Yet Recruiting
The First Affiliated Hospital, Zhejiang University School of Medicine
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.